secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001193125-23-203836
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies receives Nasdaq notice for non-compliance with MVLS minimum $50M
--------------------------------------------------------------------------------

- Received written notice from Nasdaq on Aug 3, 2023 for failing to meet $50M minimum MVLS requirement.
- Has until Jan 30, 2024 to regain compliance by closing at $50M+ for 10 consecutive business days.
- Common stock continues trading on Nasdaq Global Select under TSHA; may consider transfer to Cap Market.
- Company intends to monitor MVLS and explore available options; no immediate delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523203836/0001193125-23-203836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523203836/d471821d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-203836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer